Tesamorelin Ipamorelin Blend 18MG

What Is the Tesamorelin Ipamorelin Blend?

Tesamorelin Ipamorelin Blend is a dual-peptide research formulation combining two growth hormone-releasing compounds in a single lyophilised vial. This Tesamorelin Ipamorelin Blend supplies 12mg of Tesamorelin — a synthetic analogue of growth hormone-releasing hormone (GHRH) — alongside 6mg of Ipamorelin, a selective growth hormone secretagogue receptor (GHSR) agonist. Together, the Tesamorelin Ipamorelin Blend provides researchers with a complementary GHRH/GHSR system for in vitro and in vivo studies of growth hormone axis regulation, pituitary signalling, and downstream metabolic effects.

The combination of Tesamorelin and Ipamorelin in a single vial is intended to facilitate research protocols that require concurrent activation of both GHRH receptor and GHSR pathways. Each component is independently validated to ≥99% purity by HPLC, and the Tesamorelin Ipamorelin Blend is supplied by Arma Peptides exclusively for controlled scientific research.

Tesamorelin: Research Background

Tesamorelin is a 44-amino acid synthetic peptide analogue of endogenous growth hormone-releasing hormone (GHRH). Tesamorelin retains the full receptor-binding sequence of native GHRH and has been studied in research contexts examining pituitary somatotroph stimulation, GH pulse dynamics, and IGF-1 axis modulation. The structural stability of Tesamorelin relative to native GHRH — conferred by a trans-3-hexenoic acid modification at the N-terminus — has made Tesamorelin a widely referenced GHRH analogue in preclinical research literature.

Tesamorelin has been investigated across a range of experimental models involving lipid metabolism, adipose tissue dynamics, and hypothalamic-pituitary axis function. Structural and pharmacological data for Tesamorelin are indexed at PubChem (NIH).

Ipamorelin: Research Background

Ipamorelin is a pentapeptide GHSR agonist with high selectivity for the growth hormone secretagogue receptor subtype 1a (GHSR-1a). In preclinical experimental models, Ipamorelin has been shown to stimulate pulsatile GH release without significantly elevating cortisol, prolactin, or ACTH — a selectivity profile that has made Ipamorelin a commonly used reference compound in GH secretagogue research. Ipamorelin operates via a ghrelin-independent receptor mechanism, activating GHSR through a structurally distinct binding mode.

Ipamorelin research has been documented across neuroendocrine, metabolic, and tissue repair models. Bioactivity data for Ipamorelin are available in the ChEMBL database (EMBL-EBI), with peer-reviewed literature indexed at NCBI.

Mechanism of Action

The Tesamorelin Ipamorelin Blend engages two complementary receptor systems within the growth hormone axis. Tesamorelin acts at pituitary GHRH receptors, stimulating endogenous GH release through the adenylyl cyclase / cAMP pathway. Ipamorelin acts at GHSR-1a receptors, triggering GH secretion via a distinct intracellular signalling cascade. In research models, concurrent GHRH receptor and GHSR activation by the Tesamorelin Ipamorelin Blend has been studied for synergistic effects on GH pulse amplitude and downstream IGF-1 production.

The dual-pathway mechanism of the Tesamorelin Ipamorelin Blend allows researchers to examine whether combined GHRH/GHSR stimulation produces additive or synergistic GH release relative to either compound used independently — a key question in GH secretagogue pharmacology research.

Research Applications

The Tesamorelin Ipamorelin Blend is referenced across a range of experimental models. Documented research applications include:

• Dual GHRH receptor / GHSR-1a activation studies in pituitary cell models
• GH pulse dynamics and IGF-1 axis modulation in in vivo rodent models
• Comparative GH secretagogue profiling — combined versus single-agent protocols
• Adipose tissue and lipid metabolism investigations in GH-deficient experimental models
• Neuroendocrine axis regulation and hypothalamic-pituitary function research
• Tissue repair, lean mass, and body composition models
• Sleep architecture and GH secretion pattern studies

Product Specifications

Storage & Handling

Tesamorelin Ipamorelin Blend 18mg should be stored at –20°C in its original sealed vial, protected from light and moisture. Once reconstituted for experimental use, aliquots of the Tesamorelin Ipamorelin Blend should be kept at 4°C and used promptly in accordance with standard peptide handling protocols. Reconstitution for laboratory purposes is typically performed using sterile water or bacteriostatic water. All handling must comply with applicable institutional biosafety guidelines and relevant regulatory requirements.

Related Research Peptides

Researchers working with the Tesamorelin Ipamorelin Blend in GH axis or metabolic models may also find the following Arma Peptides compounds relevant:

• Ipamorelin 5mg — individual GHSR agonist for single-agent GH secretagogue research
• Ipamorelin 10mg — higher-quantity Ipamorelin for extended research protocols
• CJC-1295 No DAC 10mg — GHRH analogue studied in pulsatile GH release models
• CJC-1295 with DAC 10mg — long-acting GHRH analogue for extended GH axis research
• GHRP-6 5mg — first-generation GH secretagogue investigated in GH and appetite-signalling models

Research Disclaimer

Tesamorelin Ipamorelin Blend 18mg is supplied by Arma Peptides strictly for controlled scientific research. Not intended for human or veterinary use. All handling must comply with applicable institutional and regulatory guidelines.